LIMN.US Liminatus Pharma, Inc. Class A Common Stock
- Market cap
- USD 4.02M
- P/E
- -
- P/B
- 13.36x
- ROE
- -1,683.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LIMN.US undervalued?
Graham numberThe Graham number of Liminatus Pharma, Inc. Class A Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Liminatus Pharma, Inc. Class A Common Stock fundamental analysis
No fundamental analysis for Liminatus Pharma, Inc. Class A Common Stock yet.
Liminatus Pharma, Inc. Class A Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Full company profileLiminatus Pharma, Inc. Class A Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Liminatus Pharma, Inc. Class A Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | - | -1.97K |
| Operating Income | -2.53M | -2.71M | -2.59M | -2.91M | -2.97M | -4.96M |
| EBITDA | 4.37M | -2.71M | -1.09M | -2.75M | -9.99M | -4.97M |
| Net Income | 4.37M | -2.93M | -1.23M | -2.90M | -10.2M | -5.06M |
| EPS | 6.33 | -4.25 | -7.65 | -20 | -21 | -11 |
| Balance Sheet | ||||||
| Total Assets | 276M | 15.5M | 4.50M | 2.83M | 513K | 3.40M |
| Total Liabilities | 21.6M | 14.2M | 15.2M | 18.7M | 10.3M | 3.10M |
| Shareholders' Equity | 255M | 1.29M | -10.7M | -15.9M | -9.81M | 301K |
| Cash & Short-term Investments | 336K | 5.05M | 434K | 805K | 338K | 3.02M |
| Total Debt | 90.0K | 16.5M | 16.1M | 5.12M | 1.44M | 1.44M |
| Cash Flow | ||||||
| Operating Cash Flow | -1.22M | -869K | -3.35M | -3.11M | -9.96M | -5.97M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 13.1K | 0.00 |
| Free Cash Flow | -1.22M | -869K | -3.35M | -3.11M | -9.98M | -5.97M |
| Ratios | ||||||
| ROE | 1.7% | -226.2% | - | - | - | -1,683.9% |
| ROA | 1.6% | -18.9% | -27.2% | -102.7% | -1,990.4% | -148.7% |
| Debt to Equity | 0.00x | 12.75x | - | - | - | 4.80x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Liminatus Pharma, Inc. Class A Common Stock dividends
Liminatus Pharma, Inc. Class A Common Stock has not paid dividends in the last 5 fiscal years.
Last stock split: 1:50 on Aug 21, 2026.
Who owns Liminatus Pharma, Inc. Class A Common Stock
- Insiders 27.28%
- Institutions 5.52%
- Public & others 67.21%
- Shares outstanding 1.34M
- Free float 1.02M
Top funds holding LIMN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 39.7K | 2.96% | 0.00% | Aug 2026 |
| Fidelity Extended Market Index | 2.41K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 161.00 | 0.01% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 124.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding LIMN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| XTX Topco Ltd | 222K | 0.33% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 138K | 0.21% | +17.52% | Jun 2026 |
| Citadel Advisors Llc | 56.1K | 0.08% | -91.72% | Jun 2026 |
| Vanguard Capital Management, LLC | 50.4K | 0.08% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 40.2K | 0.06% | 0.00% | Jun 2026 |
| StoneX Group Inc | 26.1K | 0.04% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 23.0K | 0.03% | 0.00% | Jun 2026 |
| State Street Corp | 19.0K | 0.03% | 0.00% | Jun 2026 |
| UBS Group AG | 16.7K | 0.02% | -69.35% | Jun 2026 |
| JustInvest LLC | 13.1K | 0.02% | -62.12% | Jun 2026 |
| Tower Research Capital LLC | 7.09K | 0.01% | -6.26% | Jun 2026 |
| Barclays PLC | 4.29K | 0.01% | 0.00% | Jun 2026 |
| BlackRock Inc | 313.00 | 0.00% | -97.64% | Jun 2026 |
| Cygnus Capital Advisors, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Virtu Financial LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Liminatus Pharma, Inc. Class A Common Stock company profile
- Company name
- Liminatus Pharma, Inc. Class A Common Stock
- Ticker
- LIMN.US
- Exchange
- USA Stocks
- Listed since
- May 1, 2025
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 12611 Hiddencreek Way, Cerritos, CA, United States, 90703
- Phone
- 213 273 5453
- Website
- liminatuspharma.com
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Liminatus Pharma, Inc. Class A Common Stock management
4- Mr. Chris Kim J.D., L.L.M.CEO, Chairman & President · born 1960
- Mr. Scott DamChief Financial Officer · born 1979
- Dr. Beom Kyu ChoiChief Technology Officer & Member of Scientific Advisory Board · born 1972
- Dr. Byong Chul Yoo Ph.D.Chief Science Officer & Member of Scientific Advisory Board · born 1973